Susceptibility to alcohol-induced liver disease differs considerably among individuals, making it difficult to predict who will develop liver disease by how much they drink. Abstinence is the cornerstone of management for alcohol-induced liver disease. Fatty liver and alcoholic hepatitis are frequently reversible, and survival is improved among patients who abstain from alcohol, including those with cirrhosis. Liver transplantation is the only effective treatment for terminally ill patients. It is indicated for patients who are already receiving and who can tolerate opioid therapy for their underlying persistent cancer pain.
Pain relief can occur for up to several hours after taking the medication.
Actiq is in the form of a flavored sugar lozenge that dissolves slowly in the mouth until the medication is consumed. Applications must be submitted by April 1, 1999. Membership in the AAFP is not a prerequisite for submission. Applications may be submitted in two different categories. The international attendee classification is open to anyone outside the United States who conducted clinical or educational research relevant to family medicine.